MaltSci 麦伴科研

Appearance

Popular Reports / Immunology

This report is written by MaltSci based on the latest literature and research findings

What is the role of inflammation in disease? ​

Abstract ​

Inflammation is a complex biological response that serves as a fundamental mechanism for the body to defend against pathogens and initiate tissue repair. However, dysregulated inflammation can lead to chronic diseases, posing significant health challenges globally. This review examines the multifaceted role of inflammation in various diseases, including autoimmune disorders, cardiovascular diseases, cancer, and neurodegenerative diseases. We begin by defining inflammation and outlining its phases, emphasizing its protective and pathological aspects. In autoimmune diseases, chronic inflammation results from an inappropriate immune response against self-tissues, with key cytokines driving tissue damage. In cardiovascular diseases, particularly atherosclerosis, inflammation is central to plaque formation and instability, highlighting the importance of inflammatory biomarkers for risk assessment. In cancer, the tumor microenvironment is influenced by inflammatory processes that promote tumor growth and metastasis, suggesting that targeting inflammation could enhance therapeutic efficacy. Finally, we explore neuroinflammation in Alzheimer's disease and multiple sclerosis, where inflammation contributes to neurodegeneration. Overall, this review integrates current knowledge to underscore the need for innovative therapeutic strategies that address the underlying inflammatory processes in disease management, ultimately aiming to improve patient outcomes.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 The Biological Basis of Inflammation
    • 2.1 Definition and Phases of Inflammation
    • 2.2 Key Players in the Inflammatory Response
  • 3 Inflammation in Autoimmune Diseases
    • 3.1 Mechanisms of Autoimmunity
    • 3.2 Case Studies: Rheumatoid Arthritis and Lupus
  • 4 Inflammation and Cardiovascular Disease
    • 4.1 Role of Inflammation in Atherosclerosis
    • 4.2 Inflammatory Biomarkers in Cardiovascular Risk Assessment
  • 5 Inflammation in Cancer
    • 5.1 Tumor Microenvironment and Inflammatory Cells
    • 5.2 Therapeutic Targeting of Inflammation in Cancer Treatment
  • 6 Neuroinflammation and Neurodegenerative Diseases
    • 6.1 The Role of Inflammation in Alzheimer's Disease
    • 6.2 Mechanisms of Neuroinflammation in Multiple Sclerosis
  • 7 Conclusion

1 Introduction ​

Inflammation is a complex biological response that plays a pivotal role in the body’s defense mechanisms against pathogens, injury, and stress. It is characterized by a series of well-coordinated cellular and molecular events, including the recruitment of immune cells, the release of signaling molecules, and changes in vascular permeability. While inflammation is essential for healing and recovery, its dysregulation can lead to a range of chronic inflammatory diseases, which pose significant health challenges globally. Chronic inflammation has been implicated in the pathogenesis of numerous conditions, including autoimmune diseases, cardiovascular disorders, cancer, and neurodegenerative diseases, highlighting the dual nature of inflammation as both a protective and a pathological process [1][2].

The significance of inflammation in disease processes cannot be overstated. Understanding the mechanisms underlying inflammatory responses is crucial for developing innovative therapeutic strategies that harness its beneficial effects while mitigating its harmful consequences. Chronic inflammation is now recognized as a critical factor in the development and progression of various diseases, making it a focal point of research in biomedical science. For instance, the role of inflammation in atherosclerosis has been extensively studied, revealing that inflammatory cells and mediators contribute to plaque formation and instability, leading to acute cardiovascular events [3][4]. Similarly, in cancer, the tumor microenvironment is heavily influenced by inflammatory processes, which can promote tumor growth and metastasis [5][6].

Current research has made significant strides in elucidating the complex interactions between inflammation and disease. Advances in immunology have provided insights into the signaling pathways and cellular players involved in the inflammatory response, including the roles of innate immune cells, cytokines, and the inflammasome [7][8]. Furthermore, the interplay between inflammation and metabolic processes has opened new avenues for therapeutic interventions, particularly in conditions like obesity and diabetes, where chronic inflammation is a key feature [9][10].

This review is organized into several key sections that explore the multifaceted role of inflammation in various diseases. The first section provides an overview of the biological basis of inflammation, including its definition, phases, and key players involved in the inflammatory response. The subsequent sections delve into specific disease contexts: autoimmune diseases, where we will discuss mechanisms of autoimmunity and case studies such as rheumatoid arthritis and lupus; cardiovascular diseases, focusing on the role of inflammation in atherosclerosis and the use of inflammatory biomarkers for risk assessment; and cancer, examining the tumor microenvironment and therapeutic targeting of inflammation. Finally, we will explore neuroinflammation and its implications in neurodegenerative diseases like Alzheimer's disease and multiple sclerosis.

By integrating current knowledge from diverse fields, this review aims to highlight the critical balance between inflammation's protective and pathological roles in health and disease. Through this exploration, we hope to illuminate potential therapeutic strategies that could effectively target inflammation in the management of various diseases, ultimately enhancing patient outcomes and quality of life. Understanding the dual nature of inflammation not only enriches our comprehension of disease mechanisms but also paves the way for innovative treatments that address the underlying inflammatory processes contributing to disease pathogenesis.

2 The Biological Basis of Inflammation ​

2.1 Definition and Phases of Inflammation ​

Inflammation is a complex biological response of tissues to harmful stimuli, such as pathogens, cell damage, or irritants. It is considered a protective mechanism that aims to eliminate the initial cause of cell injury, clear out necrotic cells and tissues, and initiate tissue repair. However, while acute inflammation is generally beneficial, chronic inflammation can lead to tissue damage and the development of various diseases.

The phases of inflammation typically include the initiation phase, where inflammatory mediators are released in response to injury or infection; the amplification phase, where immune cells are recruited to the site of inflammation; and the resolution phase, where the inflammatory response is downregulated, and healing occurs. If the inflammatory response fails to resolve, it can become chronic, leading to pathological conditions.

Inflammation plays a pivotal role in numerous diseases. For instance, in atherosclerosis, inflammation is central to the initiation and progression of the disease. The presence of inflammatory cells in atheromatous plaques contributes to acute coronary events, and cytokines, adhesion molecules, and growth factors are involved in the inflammatory process that drives plaque instability (Kaski 2000; Tiong and Brieger 2005) [3][4].

In chronic inflammatory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD), inflammation in the airways is a significant factor in disease pathogenesis. The NLRP3 inflammasome, a multimeric protein complex, has been implicated in the inflammation observed in these respiratory diseases, highlighting the importance of understanding the pathways that drive this chronic inflammation (Birrell and Eltom 2011) [7].

In the context of autoimmune diseases, persistent inflammation can result from the continuous activation of the immune system, leading to tissue damage. Pro-inflammatory cytokines like IL-1 and TNF are critical mediators in these conditions, underscoring the potential for targeted therapies aimed at modulating inflammatory responses (Tincani et al. 2007) [11].

Moreover, the relationship between inflammation and cancer is well-established, particularly in inflammatory bowel diseases (IBD) where chronic inflammation is a risk factor for the development of colorectal cancer (CRC). The ghrelin system has been identified as playing a role in the pathogenesis of IBD and its progression to CRC, emphasizing the multifaceted role of inflammation in disease (Kasprzak and Adamek 2022) [12].

In summary, inflammation serves as a double-edged sword in disease pathology. While it is essential for host defense and tissue repair, its dysregulation can lead to chronic conditions, tissue damage, and the progression of various diseases, including cardiovascular diseases, respiratory disorders, autoimmune diseases, and cancers. Understanding the biological basis and phases of inflammation is crucial for developing effective therapeutic strategies to manage inflammatory diseases.

2.2 Key Players in the Inflammatory Response ​

Inflammation is a complex biological response that serves as a crucial mechanism for the body to defend against infection, injury, and harmful stimuli. It is characterized by a cascade of molecular and cellular events aimed at eliminating the initial cause of cell injury, clearing out damaged cells, and initiating tissue repair. However, the role of inflammation in disease is multifaceted, as it can also lead to pathological conditions when the inflammatory response becomes chronic or dysregulated.

One key aspect of inflammation is its role in the pathogenesis of various chronic diseases, including cardiovascular disease, autoimmune disorders, and cancer. For instance, in the context of atherosclerosis, inflammation is recognized as pivotal in the initiation, progression, and complications of the disease. The inflammatory response is driven by various cytokines and immune cells, which participate in processes such as endothelial dysfunction, foam cell formation, and plaque progression [4].

Chronic inflammation can result from persistent activation of the immune system and is associated with numerous diseases. It has been suggested that inflammation may act as a potent promoter of injury and disease, linking stress responses to pathological conditions [13]. In particular, inflammatory processes are implicated in the development of inflammatory bowel diseases (IBD), where dysbiosis of the gut microbiota can either be a cause or consequence of inflammation [14].

Key players in the inflammatory response include various immune cells such as macrophages, neutrophils, and lymphocytes. Macrophages, for example, can adopt different activation states that lead to either pro-inflammatory or anti-inflammatory responses, thus playing a dual role in inflammation and tissue repair [15]. Neutrophils are among the first responders to sites of inflammation, contributing to pathogen clearance but also potentially causing tissue damage if the response is excessive or prolonged [16].

The regulatory mechanisms of inflammation are complex and involve numerous signaling pathways and mediators. For example, pro-inflammatory cytokines such as IL-1 and TNF are central to the inflammatory response and have been targeted in therapies for autoimmune diseases [11]. The balance between pro-inflammatory and anti-inflammatory signals is critical for maintaining homeostasis; disruptions in this balance can lead to chronic inflammatory conditions [17].

Moreover, inflammation is also linked to metabolic disorders, where adipose tissue inflammation plays a significant role in insulin resistance and obesity [18]. The interplay between inflammation and metabolic processes highlights the systemic implications of inflammatory responses beyond localized tissue injury.

In summary, inflammation serves as both a protective mechanism and a pathological process, depending on its regulation and context. Understanding the biological basis of inflammation and its key players is essential for developing therapeutic strategies aimed at mitigating the adverse effects of chronic inflammation in various diseases.

3 Inflammation in Autoimmune Diseases ​

3.1 Mechanisms of Autoimmunity ​

Inflammation plays a critical role in various diseases, particularly in autoimmune disorders, where it can lead to chronic tissue damage and dysfunction. Inflammation is primarily a protective response aimed at eliminating pathogens and repairing tissue, but in autoimmune diseases, this response becomes dysregulated. This dysregulation results in the perpetual activation of the inflammatory process, which is sustained by pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor (TNF) [11].

Autoimmune diseases are characterized by an inappropriate immune response against the body’s own tissues, often involving complex interactions between innate and adaptive immunity. In these conditions, inflammation is not merely a response to infection but rather a driving force that contributes to disease pathology. The activation of the innate immune system, in particular, plays a crucial role in the onset and progression of these diseases [19]. For instance, autoinflammatory syndromes are marked by unchecked activation of the innate immune system, leading to episodes of systemic inflammation without the typical features of autoimmune disorders [20].

Cytokines, which are key signaling molecules in the immune response, have a dual role in autoimmune diseases. They can promote inflammation, contributing to tissue damage, while also regulating immune responses. Notable cytokines involved in this process include TNF-α, IL-1, IL-6, IL-17, and IL-23, all of which have been implicated in the pathogenesis of various autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease [21]. For example, IL-1 and TNF-α are effector cytokines that trigger inflammatory events leading to tissue destruction and remodeling in autoimmune conditions [22].

The mechanisms underlying autoimmunity are complex and multifactorial. Genetic predisposition, environmental triggers, and epigenetic factors contribute to the loss of self-tolerance and the subsequent activation of autoreactive immune cells [23]. Moreover, studies have indicated that the malfunction of the NLRP3 inflammasome, a key sensor of tissue damage, plays a significant role in driving autoinflammatory and autoimmune diseases [24]. The NLRP3 inflammasome is involved in the production of pro-inflammatory cytokines, further exacerbating inflammation and tissue damage [25].

In summary, inflammation is a central feature of autoimmune diseases, where it can lead to chronic inflammation and tissue damage due to the dysregulated immune response. The interplay between various cytokines and immune cells is critical in understanding the pathogenesis of these diseases, providing potential targets for therapeutic intervention. Enhanced knowledge of the mechanisms involved in inflammation and autoimmunity could pave the way for the development of more effective treatments for these debilitating conditions.

3.2 Case Studies: Rheumatoid Arthritis and Lupus ​

Inflammation plays a pivotal role in the pathogenesis of autoimmune diseases, particularly in conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). These diseases are characterized by an inappropriate immune response against self-antigens, leading to chronic inflammation and tissue damage.

In rheumatoid arthritis, inflammation is primarily driven by the innate immune system, which includes the activation of various innate immune cells such as monocytes, macrophages, and dendritic cells. These cells contribute to the inflammatory milieu by secreting pro-inflammatory cytokines and chemokines, which recruit additional immune cells to the synovium, resulting in persistent joint inflammation and damage [26]. The pathogenesis of RA involves a complex interplay between the innate and adaptive immune systems, with innate immune responses being crucial in the early stages of disease development [26].

The role of toll-like receptors (TLRs) in the immune response is also significant in the context of autoimmune diseases. TLRs are known to modulate inflammation and have been implicated in the initiation and perpetuation of inflammatory autoimmune diseases. Specifically, targeting TLR activation may offer therapeutic potential in conditions such as RA and SLE, although more research is needed to understand the mechanisms involved and the long-term effects of such interventions [27].

In systemic lupus erythematosus, inflammation is similarly driven by aberrant immune responses, where autoantibodies target various tissues, leading to widespread inflammation and organ damage. The chronic inflammation associated with SLE is influenced by both innate and adaptive immune mechanisms, and it can result in the activation of inflammasomes and the production of cytokines that exacerbate tissue injury [28].

The association between inflammation and the risk of developing cardiovascular diseases in patients with RA and SLE further highlights the systemic impact of chronic inflammation. In these conditions, traditional cardiovascular risk factors are often insufficient to explain the heightened risk of atherosclerosis and related complications, indicating that inflammatory processes may be central to the pathogenesis of cardiovascular disease in these populations [29].

In summary, inflammation is a central feature of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, where it contributes to disease onset, progression, and the development of comorbidities. Understanding the mechanisms underlying inflammation in these diseases is crucial for developing targeted therapies aimed at modulating immune responses and alleviating the burden of these chronic conditions.

4 Inflammation and Cardiovascular Disease ​

4.1 Role of Inflammation in Atherosclerosis ​

Inflammation plays a pivotal role in the pathogenesis of cardiovascular diseases, particularly atherosclerosis, which is recognized as a chronic inflammatory condition. The relationship between inflammation and atherosclerosis has been extensively studied, revealing that inflammation is not merely a response to injury but a central mechanism driving the progression of this disease.

Atherosclerosis is characterized by the formation of plaques in the arterial wall, which consist of lipids, immune cells, and connective tissue. The inflammatory response is crucial at all stages of atherogenesis, from the initial fatty streak formation to plaque rupture, which can lead to acute coronary events. Chronic inflammation, as highlighted by various studies, contributes significantly to the development and destabilization of atherosclerotic plaques, making them prone to rupture and thrombosis [30][31][32].

The involvement of inflammatory cells, particularly monocytes and macrophages, is critical in this process. These cells infiltrate the arterial wall, where they become activated and contribute to the formation of foam cells—an early sign of atherosclerosis. Cytokines and chemokines produced during the inflammatory response further exacerbate the condition by promoting endothelial dysfunction and increasing vascular permeability, facilitating the accumulation of lipids and immune cells within the arterial intima [33][34].

Recent clinical and experimental evidence supports the notion that inflammation is not only a consequence of atherosclerosis but also a driving force behind its progression. For instance, elevated levels of inflammatory markers, such as high-sensitivity C-reactive protein (hs-CRP), have been associated with an increased risk of cardiovascular events, indicating that inflammation serves as a predictive biomarker for atherosclerotic disease [35][36]. Furthermore, therapeutic strategies targeting inflammation have emerged as promising approaches to reduce cardiovascular risk. Clinical trials have demonstrated that anti-inflammatory therapies can improve outcomes in patients with atherosclerotic cardiovascular disease, highlighting the potential of these interventions in managing residual cardiovascular risk [32][37].

The understanding of the interplay between lipids, inflammation, and immune responses has led to the recognition of atherogenesis as an active process rather than a passive accumulation of cholesterol. This paradigm shift emphasizes the importance of targeting inflammation in therapeutic strategies, suggesting that addressing inflammatory pathways could significantly alter the course of atherosclerosis and improve patient outcomes [36][38].

In conclusion, inflammation is a fundamental component of atherosclerosis, influencing its initiation, progression, and complications. The identification of inflammatory pathways and markers has opened new avenues for risk stratification and therapeutic interventions in cardiovascular disease, underscoring the critical need for ongoing research in this area to develop effective anti-inflammatory strategies to combat atherosclerosis and its associated cardiovascular risks [39][40].

4.2 Inflammatory Biomarkers in Cardiovascular Risk Assessment ​

Inflammation plays a crucial role in the pathogenesis and progression of cardiovascular diseases (CVDs). It is increasingly recognized as a significant underlying mechanism in various cardiovascular conditions, including hypertension, atherosclerosis, and coronary artery disease. The relationship between inflammation and cardiovascular health is complex, involving a variety of inflammatory biomarkers that can serve as indicators of disease risk and progression.

Hypertension, one of the primary risk factors for CVDs, is closely linked to inflammatory processes. Research indicates that inflammatory biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) are not only indicators of inflammation but also active participants in the mechanisms that elevate blood pressure. These cytokines contribute to endothelial dysfunction, oxidative stress, and immune system activation, all of which are pivotal in the development of hypertension [41].

Atherosclerosis, the main pathological basis for CVD, is also significantly influenced by inflammation. Inflammatory processes are considered critical in the initiation and progression of atherosclerosis, involving numerous cellular mediators. Biomarkers that can assess vascular inflammation are essential for understanding the progression of atherosclerosis and the associated cardiovascular risk. The identification of novel inflammatory molecules, alongside traditional risk factors, enhances the stratification of patients at risk for cardiovascular events [42].

In the context of coronary artery disease, inflammation has been shown to correlate with adverse cardiovascular events. A study involving 1,090 patients undergoing coronary angiography identified distinct clusters of inflammatory biomarkers that correlated with major adverse cardiovascular events (MACE). Notably, higher levels of specific inflammatory markers, such as IL-6 and high-sensitivity CRP, were associated with increased risk of MACE, indicating their potential utility in cardiovascular risk assessment [43].

Moreover, the interplay between inflammation and other risk factors, such as heart rate, further complicates the cardiovascular risk landscape. Elevated resting heart rate has been shown to amplify the adverse effects of inflammation on cardiovascular mortality, highlighting the need for a comprehensive approach in managing patients at risk [44].

In summary, inflammation serves as a critical determinant in the development and progression of cardiovascular diseases. Inflammatory biomarkers not only provide insights into the underlying pathophysiological mechanisms but also serve as valuable tools for risk stratification and management of patients with cardiovascular conditions. Understanding these relationships enhances the potential for targeted therapeutic strategies aimed at mitigating inflammation and improving cardiovascular outcomes [45][46].

5 Inflammation in Cancer ​

5.1 Tumor Microenvironment and Inflammatory Cells ​

Inflammation plays a pivotal role in the context of cancer, particularly through its influence on the tumor microenvironment (TME) and the behavior of inflammatory cells. The TME is a complex network comprising cancer cells, immune cells, stromal cells, and soluble factors, all of which interact dynamically to affect tumor progression and therapeutic responses.

Chronic inflammation is closely associated with various stages of cancer development, including initiation, promotion, invasion, and metastasis. Inflammatory cells and mediators are essential components of the TME, significantly contributing to tumor growth and metastasis. For instance, cancer-associated inflammatory cells (CICs) interact with cancer cells, promoting a microenvironment conducive to tumor proliferation and immune evasion. This interaction is often facilitated by pro-inflammatory cytokines, such as interleukins and tumor necrosis factor-alpha (TNF-α), which can either promote or inhibit cancer progression depending on the context[47][48].

The presence of inflammatory cytokines in the TME is linked to advanced cancer stages and can result in resistance to immunotherapy, leading to poor prognoses. Pro-inflammatory cytokines are associated with decreased objective response rates, disease control rates, and overall survival in various cancers, including colorectal, pancreatic, breast, gastric, lung, and prostate cancers[47].

Moreover, the TME facilitates a chronic inflammatory state that alters immune cell function, leading to immunosuppression. This suppression is characterized by the presence of immune/inflammatory cells, such as tumor-associated macrophages and myeloid-derived suppressor cells, which release cytokines that inhibit effective antitumor immune responses. As a result, tumor cells may thrive and evade immune detection[49].

The interplay between inflammation and the TME is also critical for understanding cancer metastasis. Inflammatory components contribute to the invasive and metastatic traits of cancer cells, with cytokines and chemokines orchestrating the recruitment of immune cells that can further promote tumor spread[50].

Targeting inflammation presents a potential therapeutic strategy in cancer treatment. Inflammation-targeted therapies aim to modulate the TME, enhance antitumor immunity, and improve the efficacy of existing treatments. By understanding the roles of inflammatory mediators and the complex interactions within the TME, researchers hope to develop more effective cancer therapies that not only target cancer cells but also address the underlying inflammatory processes that facilitate tumor growth and metastasis[48][51].

In summary, inflammation plays a dual role in cancer, acting as both a promoter of tumorigenesis and a potential target for therapeutic intervention. The dynamic interactions within the TME, influenced by inflammatory cells and cytokines, are critical to understanding cancer biology and developing novel treatment strategies.

5.2 Therapeutic Targeting of Inflammation in Cancer Treatment ​

Inflammation plays a pivotal role in the pathogenesis of various diseases, particularly cancer. It is an essential component of the immune response that protects the host against pathogens and facilitates tissue repair. However, chronic inflammation is a critical factor in cancer development and progression, affecting every stage of tumor development, from initiation and promotion to invasion and metastasis [48]. Tumors often create an inflammatory microenvironment that induces angiogenesis, immune suppression, and malignant growth [48]. This complex interplay between cancer cells and immune cells within the tumor microenvironment drives cancer progression through various molecular mechanisms [51].

Chronic inflammation can be triggered by several factors, including infections, obesity, and environmental toxins, and is strongly linked to increased cancer risk [48]. The inflammatory response can contribute to tumorigenesis by enhancing genomic instability, promoting cell proliferation, and providing a supportive microenvironment for tumor growth [52]. For instance, inflammatory cells secrete mediators such as cytokines and chemokines, which can influence tumor behavior and immune responses [53].

Despite its protumorigenic effects, inflammation also presents opportunities for therapeutic intervention. Recent studies have highlighted the potential of targeting inflammation in cancer therapy. Inflammation-targeted agents can not only suppress cancer development but also improve the efficacy of other therapeutic modalities, such as chemotherapy and immunotherapy [51]. For example, the use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced cancer incidence and improved treatment outcomes [54].

Therapeutic strategies targeting inflammation in cancer can involve inhibiting inflammatory mediators, blocking the recruitment of myeloid cells, and modulating the immune response within the tumor microenvironment [53]. These approaches aim to re-educate the tumor microenvironment to enhance antitumor immunity and overcome the immunosuppressive effects of chronic inflammation [52].

Moreover, specific inflammatory cytokines have been identified as critical players in cancer progression, making them attractive targets for therapy [47]. For instance, interleukin-1β (IL-1β) has shown promise as a target in lung cancer treatment, with studies indicating that its blockade can lead to a reduced incidence of lung cancer [55].

In summary, inflammation is a double-edged sword in cancer, serving both as a promoter of tumorigenesis and as a potential target for therapeutic intervention. Understanding the dual role of inflammation in cancer biology is crucial for developing effective strategies to manipulate the tumor microenvironment and enhance treatment efficacy. By targeting the inflammatory pathways involved in cancer, researchers aim to improve clinical outcomes and develop novel therapeutic agents [56].

6 Neuroinflammation and Neurodegenerative Diseases ​

6.1 The Role of Inflammation in Alzheimer's Disease ​

Inflammation plays a crucial role in the pathogenesis of Alzheimer's disease (AD), a complex neurodegenerative disorder characterized by cognitive decline and memory loss. Multiple studies have established that neuroinflammation, marked by the activation of glial cells and the release of pro-inflammatory cytokines, is a significant contributor to the disease's progression and development.

Neuroinflammation in AD is initiated by various stimuli, including the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles, which are considered hallmarks of the disease. Microglia, the resident immune cells of the central nervous system (CNS), become activated in response to these pathological changes. This activation leads to the release of inflammatory mediators, including cytokines such as tumor necrosis factor (TNF) and interleukins, which can exacerbate neuronal damage and promote neurodegeneration [57][58].

Evidence suggests that systemic inflammation also plays a role in the development of AD. Studies have indicated that elevated levels of systemic inflammatory markers, such as C-reactive protein (CRP), are associated with an increased risk of cognitive decline and dementia [59][60]. The interplay between systemic and central inflammation may create a feedback loop that accelerates neurodegenerative processes [61].

Furthermore, genetic factors influencing the immune response can modulate the risk of developing AD. Variations in cytokine genes have been linked to the age of onset and progression of the disease, indicating that individual genetic predispositions can affect inflammatory responses and, consequently, disease outcomes [62].

The role of inflammasomes, which are multiprotein complexes that activate pro-inflammatory cytokines like interleukin-1β (IL-1β), has also been highlighted in the context of AD. Dysregulation of inflammasome activity contributes to chronic neuroinflammation, further linking inflammation to the disease's pathology [63].

Therapeutically, targeting neuroinflammation presents a promising strategy for AD management. Research indicates that modulating the inflammatory response, either through anti-inflammatory drugs or immunotherapies aimed at regulating microglial activity, could slow disease progression and improve cognitive outcomes [64][65]. However, clinical trials have yielded mixed results, underscoring the complexity of inflammation's role in AD and the need for further research to identify effective interventions [66].

In summary, inflammation, particularly neuroinflammation, is intricately linked to the pathogenesis of Alzheimer's disease. It contributes to the initiation and progression of the disease through the activation of immune responses that can exacerbate neuronal damage. Understanding the mechanisms of inflammation in AD is critical for developing targeted therapeutic strategies aimed at mitigating its impact on cognitive health.

6.2 Mechanisms of Neuroinflammation in Multiple Sclerosis ​

Neuroinflammation plays a critical role in the pathogenesis of multiple sclerosis (MS), which is characterized as a chronic inflammatory and degenerative disease of the central nervous system (CNS). Inflammation is a common feature observed throughout all stages of MS, both within and around lesions, and it can have both beneficial and detrimental effects on disease progression. The involvement of inflammation in MS is primarily attributed to the activation of immune cells, particularly microglia and astrocytes, which can trigger a chronic inflammatory response that contributes to neuronal damage.

A key mechanism by which inflammation influences neurodegeneration in MS involves the release of pro-inflammatory cytokines and the activation of signaling pathways, such as the NF-κB and MAPK pathways. This inflammatory response can lead to a cascade of events that promote demyelination and neuronal cell death. Specifically, the presence of inflammatory mediators like IL-1β, IL-6, and TNF-α can exacerbate the neurodegenerative processes by inducing oxidative stress and promoting further immune cell infiltration into the CNS [67][68].

The interplay between neuroinflammation and neurodegeneration is complex. For instance, while inflammation can contribute to tissue damage, it may also have neuroprotective effects under certain circumstances. The release of brain-derived neurotrophic factor (BDNF) by immune cells can provide neuroprotection and modulate the inflammatory response. Understanding the dual role of inflammation in MS is crucial for developing therapeutic strategies aimed at mitigating neuroinflammation while promoting neuroprotection [69][70].

In addition, the presence of myeloid-derived suppressor cells (MDSCs) has been shown to play a pivotal role in regulating the immune response in MS. MDSCs can initially attenuate inflammation, but their prolonged expansion in chronic neuroinflammation may lead to cognitive impairment and disease exacerbation. This highlights the necessity of understanding the timing and context of immune responses in MS [71].

Overall, the mechanisms of neuroinflammation in MS illustrate a complex relationship where inflammation is a double-edged sword, contributing to both the progression and potential mitigation of neurodegenerative processes. Continued research into the specific pathways and cellular interactions involved in neuroinflammation is essential for developing targeted therapies that can effectively address the inflammatory components of MS while preserving neuronal integrity [72][73].

7 Conclusion ​

This review highlights the intricate and dual nature of inflammation in various diseases, emphasizing its critical role as both a protective mechanism and a pathological contributor. Key findings underscore that while inflammation is essential for host defense and tissue repair, its dysregulation can lead to chronic inflammatory diseases, including autoimmune disorders, cardiovascular diseases, cancer, and neurodegenerative diseases. Current research indicates that the interplay between inflammatory mediators, immune cells, and the tumor microenvironment is vital in understanding disease mechanisms and developing effective therapeutic strategies. The evaluation of inflammatory biomarkers presents promising avenues for risk assessment and treatment optimization in cardiovascular diseases. Furthermore, the understanding of neuroinflammation's role in conditions such as Alzheimer's disease and multiple sclerosis opens potential pathways for targeted interventions. Future research should focus on elucidating the precise mechanisms underlying inflammation in disease pathogenesis and exploring novel therapeutic approaches that can modulate inflammatory responses to improve patient outcomes and quality of life.

References ​

  • [1] Benjamin D Bringardner;Christopher P Baran;Timothy D Eubank;Clay B Marsh. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis.. Antioxidants & redox signaling(IF=6.1). 2008. PMID:17961066. DOI: 10.1089/ars.2007.1897.
  • [2] Francisco Victorino;Scott Alper. Identifying novel spatiotemporal regulators of innate immunity.. Immunologic research(IF=3.1). 2013. PMID:22926826. DOI: 10.1007/s12026-012-8344-0.
  • [3] J C Kaski. [Inflammation, infection and coronary artery disease: myths and realities. Special XXXV Conference of the National Congress of the Spanish Society of Cardiology].. Revista espanola de cardiologia(IF=5.9). 2000. PMID:11060248. DOI: 10.1016/s0300-8932(00)75234-1.
  • [4] Alice Y Tiong;David Brieger. Inflammation and coronary artery disease.. American heart journal(IF=3.5). 2005. PMID:16084145. DOI: 10.1016/j.ahj.2004.12.019.
  • [5] Brian W Wong;Anna Meredith;David Lin;Bruce M McManus. The biological role of inflammation in atherosclerosis.. The Canadian journal of cardiology(IF=5.3). 2012. PMID:22985787. DOI: .
  • [6] Fabíola Silva Alves-Hanna;Juniel Assis Crespo-Neto;Glenda Menezes Nogueira;Daniele Sá Pereira;Amanda Barros Lima;Thaís Lohana Pereira Ribeiro;Vitória Giovanna Rodrigues Santos;Joey Ramone Ferreira Fonseca;Fábio Magalhães-Gama;Aya Sadahiro;Allyson Guimarães Costa. Insights Regarding the Role of Inflammasomes in Leukemia: What Do We Know?. Journal of immunology research(IF=3.6). 2023. PMID:37577033. DOI: 10.1155/2023/5584492.
  • [7] Mark A Birrell;Suffwan Eltom. The role of the NLRP3 inflammasome in the pathogenesis of airway disease.. Pharmacology & therapeutics(IF=12.5). 2011. PMID:21421008. DOI: 10.1016/j.pharmthera.2011.03.007.
  • [8] Francesca Barone;Saba Nayar;Chris D Buckley. The role of non-hematopoietic stromal cells in the persistence of inflammation.. Frontiers in immunology(IF=5.9). 2012. PMID:23335923. DOI: 10.3389/fimmu.2012.00416.
  • [9] V Kumar. Inflammation research sails through the sea of immunology to reach immunometabolism.. International immunopharmacology(IF=4.7). 2019. PMID:31096130. DOI: 10.1016/j.intimp.2019.05.002.
  • [10] Jonathan S Alexander;Leonard Prouty;Ikuo Tsunoda;Chaitanya Vijay Ganta;Alireza Minagar. Venous endothelial injury in central nervous system diseases.. BMC medicine(IF=8.3). 2013. PMID:24228622. DOI: 10.1186/1741-7015-11-219.
  • [11] A Tincani;L Andreoli;C Bazzani;D Bosisio;S Sozzani. Inflammatory molecules: a target for treatment of systemic autoimmune diseases.. Autoimmunity reviews(IF=8.3). 2007. PMID:17967717. DOI: 10.1016/j.autrev.2007.03.001.
  • [12] Aldona Kasprzak;Agnieszka Adamek. Role of the Ghrelin System in Colitis and Hepatitis as Risk Factors for Inflammatory-Related Cancers.. International journal of molecular sciences(IF=4.9). 2022. PMID:36232490. DOI: 10.3390/ijms231911188.
  • [13] Irene Faenza;William L Blalock. Innate Immunity: A Balance between Disease and Adaption to Stress.. Biomolecules(IF=4.8). 2022. PMID:35625664. DOI: 10.3390/biom12050737.
  • [14] Ludovica F Buttó;Dirk Haller. Dysbiosis in intestinal inflammation: Cause or consequence.. International journal of medical microbiology : IJMM(IF=3.6). 2016. PMID:27012594. DOI: 10.1016/j.ijmm.2016.02.010.
  • [15] Xiaoquan Rao;Jixin Zhong;Qinghua Sun. The heterogenic properties of monocytes/macrophages and neutrophils in inflammatory response in diabetes.. Life sciences(IF=5.1). 2014. PMID:25264371. DOI: .
  • [16] Branka Vulesevic;Martin G Sirois;Bruce G Allen;Simon de Denus;Michel White. Subclinical Inflammation in Heart Failure: A Neutrophil Perspective.. The Canadian journal of cardiology(IF=5.3). 2018. PMID:29801737. DOI: 10.1016/j.cjca.2018.01.018.
  • [17] Romana T Netea-Maier;Theo S Plantinga;Frank L van de Veerdonk;Johannes W Smit;Mihai G Netea. Modulation of inflammation by autophagy: Consequences for human disease.. Autophagy(IF=14.3). 2016. PMID:26222012. DOI: 10.1080/15548627.2015.1071759.
  • [18] Vanessa A Guerreiro;Davide Carvalho;Paula Freitas. Obesity, Adipose Tissue, and Inflammation Answered in Questions.. Journal of obesity(IF=3.9). 2022. PMID:35321537. DOI: 10.1155/2022/2252516.
  • [19] Barbara Meier-Schiesser;Lars E French. Autoinflammatory syndromes.. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG(IF=3.8). 2021. PMID:33620111. DOI: 10.1111/ddg.14332.
  • [20] Annika Havnaer;George Han. Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment.. American journal of clinical dermatology(IF=8.8). 2019. PMID:30997665. DOI: 10.1007/s40257-019-00440-y.
  • [21] Fatima Dandash;Zahraa Salhab;Rawan Issa;Zeinab Al Dirani;Mariam Hamze;Gabriel Fares;Fatima Berro;Fatima Shaalan;Ali Hamade;Makram Merimi;Mehdi Najar;Rayan Dakroub;Douaa Khreis;Mohammad Fayyad-Kazan;Hussein Fayyad-Kazan. Targeting the double-edged sword: cytokines in the pathogenesis and treatment of autoimmune diseases.. Inflammopharmacology(IF=5.3). 2025. PMID:40580299. DOI: 10.1007/s10787-025-01817-8.
  • [22] C A Dinarello. Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases.. Seminars in immunology(IF=7.8). 1992. PMID:1320950. DOI: .
  • [23] Yasuto Araki;Toshihide Mimura. The Histone Modification Code in the Pathogenesis of Autoimmune Diseases.. Mediators of inflammation(IF=4.2). 2017. PMID:28127155. DOI: 10.1155/2017/2608605.
  • [24] Zhenyu Zhong;Elsa Sanchez-Lopez;Michael Karin. Autophagy, NLRP3 inflammasome and auto-inflammatory/immune diseases.. Clinical and experimental rheumatology(IF=3.3). 2016. PMID:27586797. DOI: .
  • [25] Tanja Fetter;Dennis Marinus de Graaf;Isabelle Claus;Joerg Wenzel. Aberrant inflammasome activation as a driving force of human autoimmune skin disease.. Frontiers in immunology(IF=5.9). 2023. PMID:37325658. DOI: 10.3389/fimmu.2023.1190388.
  • [26] Maria I Edilova;Ali Akram;Ali A Abdul-Sater. Innate immunity drives pathogenesis of rheumatoid arthritis.. Biomedical journal(IF=4.4). 2021. PMID:32798211. DOI: 10.1016/j.bj.2020.06.010.
  • [27] Felix I L Clanchy;Sandra M Sacre. Modulation of toll-like receptor function has therapeutic potential in autoimmune disease.. Expert opinion on biological therapy(IF=4.0). 2010. PMID:21039312. DOI: 10.1517/14712598.2010.534080.
  • [28] Zoltán Szekanecz;Iain B McInnes;Georg Schett;Szilvia Szamosi;Szilvia Benkő;Gabriella Szűcs. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases.. Nature reviews. Rheumatology(IF=32.7). 2021. PMID:34341562. DOI: 10.1038/s41584-021-00652-9.
  • [29] Marta Chiara Sircana;Gian Luca Erre;Floriana Castagna;Roberto Manetti. Crosstalk between Inflammation and Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Is There a Common Basis?. Life (Basel, Switzerland)(IF=3.4). 2024. PMID:38929699. DOI: 10.3390/life14060716.
  • [30] Paolo Raggi;Jacques Genest;Jon T Giles;Katey J Rayner;Girish Dwivedi;Robert S Beanlands;Milan Gupta. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions.. Atherosclerosis(IF=5.7). 2018. PMID:30055326. DOI: 10.1016/j.atherosclerosis.2018.07.014.
  • [31] Israel F Charo;Rebecca Taub. Anti-inflammatory therapeutics for the treatment of atherosclerosis.. Nature reviews. Drug discovery(IF=101.8). 2011. PMID:21532566. DOI: 10.1038/nrd3444.
  • [32] Suzanne E Engelen;Alice J B Robinson;Yasemin-Xiomara Zurke;Claudia Monaco. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?. Nature reviews. Cardiology(IF=44.2). 2022. PMID:35102320. DOI: 10.1038/s41569-021-00668-4.
  • [33] Daniel P Jones;Jyoti Patel. Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders.. Biology(IF=3.5). 2018. PMID:30453474. DOI: 10.3390/biology7040049.
  • [34] Amir Ajoolabady;Domenico Pratico;Ling Lin;Christos S Mantzoros;Suhad Bahijri;Jaakko Tuomilehto;Jun Ren. Inflammation in atherosclerosis: pathophysiology and mechanisms.. Cell death & disease(IF=9.6). 2024. PMID:39528464. DOI: 10.1038/s41419-024-07166-8.
  • [35] Paolo Calabrò;Enrica Golia;Edward T H Yeh. CRP and the risk of atherosclerotic events.. Seminars in immunopathology(IF=9.2). 2009. PMID:19415283. DOI: 10.1007/s00281-009-0149-4.
  • [36] Glaucylara Reis Geovanini;Peter Libby. Atherosclerosis and inflammation: overview and updates.. Clinical science (London, England : 1979)(IF=7.7). 2018. PMID:29930142. DOI: 10.1042/CS20180306.
  • [37] Mehdi H Shishehbor;Deepak L Bhatt. Inflammation and atherosclerosis.. Current atherosclerosis reports(IF=5.2). 2004. PMID:15023298. DOI: 10.1007/s11883-004-0102-x.
  • [38] Asra Khalid Butt;Brandon Cave;Miguel Maturana;William F Towers;Rami N Khouzam. The Role of Colchicine in Coronary Artery Disease.. Current problems in cardiology(IF=3.3). 2021. PMID:32994053. DOI: 10.1016/j.cpcardiol.2020.100690.
  • [39] Abdulhamied Alfaddagh;Seth S Martin;Thorsten M Leucker;Erin D Michos;Michael J Blaha;Charles J Lowenstein;Steven R Jones;Peter P Toth. Inflammation and cardiovascular disease: From mechanisms to therapeutics.. American journal of preventive cardiology(IF=5.9). 2020. PMID:34327481. DOI: 10.1016/j.ajpc.2020.100130.
  • [40] Alberto J Lorenzatti;Brenda M Retzlaff. Unmet needs in the management of atherosclerotic cardiovascular disease: Is there a role for emerging anti-inflammatory interventions?. International journal of cardiology(IF=3.2). 2016. PMID:27420583. DOI: .
  • [41] Panagiotis Tsioufis;Panagiotis Theofilis;Kyriakos Dimitriadis;Panayotis K Vlachakis;Panayotis Iliakis;Dimitrios Tsiachris;Konstantinos Tsioufis;Dimitris Tousoulis. Inflammatory Biomarkers in Hypertension.. Current medicinal chemistry(IF=3.5). 2025. PMID:40671233. DOI: 10.2174/0109298673348789250604113545.
  • [42] Gerasimos Siasos;Vicky Tsigkou;Evangelos Oikonomou;Marina Zaromitidou;Sotiris Tsalamandris;Konstantinos Mourouzis;Manolis Vavuranakis;Maria Anastasiou;Konstantinos Vlasis;Maria Limperi;Vasiliki Gennimata;John N Boletis;Athanasios G Papavassiliou;Dimitris Tousoulis. Circulating Biomarkers Determining Inflammation in Atherosclerosis Progression.. Current medicinal chemistry(IF=3.5). 2015. PMID:25876747. DOI: 10.2174/0929867322666150415125828.
  • [43] Reza Mohebi;Cian P McCarthy;Hanna K Gaggin;Roland R J van Kimmenade;James L Januzzi. Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography.. American heart journal(IF=3.5). 2022. PMID:35753356. DOI: 10.1016/j.ahj.2022.06.004.
  • [44] Bríain O Hartaigh;Jos A Bosch;Douglas Carroll;Karla Hemming;Stefan Pilz;Adrian Loerbroks;Marcus E Kleber;Tanja B Grammer;Joachim E Fischer;Bernhard O Boehm;Winfried März;G Neil Thomas. Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography.. European heart journal(IF=35.6). 2013. PMID:23178644. DOI: 10.1093/eurheartj/ehs396.
  • [45] Panagiota Pietri;Charalambos Vlachopoulos;Dimitris Tousoulis. Inflammation and Arterial Hypertension: From Pathophysiological Links to Risk Prediction.. Current medicinal chemistry(IF=3.5). 2015. PMID:25891108. DOI: 10.2174/0929867322666150420104727.
  • [46] Konstantinos V Voudris;Jake Chanin;Dmitriy N Feldman;Konstantinos Charitakis. Novel Inflammatory Biomarkers in Coronary Artery Disease: Potential Therapeutic Approaches.. Current medicinal chemistry(IF=3.5). 2015. PMID:25891107. DOI: 10.2174/0929867322666150420124427.
  • [47] Hyang-Mi Lee;Hye-Jin Lee;Ji-Eun Chang. Inflammatory Cytokine: An Attractive Target for Cancer Treatment.. Biomedicines(IF=3.9). 2022. PMID:36140220. DOI: 10.3390/biomedicines10092116.
  • [48] Atsushi Nishida;Akira Andoh. The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis.. Cells(IF=5.2). 2025. PMID:40214442. DOI: 10.3390/cells14070488.
  • [49] Lihong Li;Rui Yu;Tiange Cai;Zhen Chen;Meng Lan;Tengteng Zou;Bingyue Wang;Qi Wang;Yiye Zhao;Yu Cai. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment.. International immunopharmacology(IF=4.7). 2020. PMID:33182039. DOI: 10.1016/j.intimp.2020.106939.
  • [50] Yadi Wu;Binhua P Zhou. Inflammation: a driving force speeds cancer metastasis.. Cell cycle (Georgetown, Tex.)(IF=3.4). 2009. PMID:19770594. DOI: 10.4161/cc.8.20.9699.
  • [51] Manni Wang;Siyuan Chen;Xuemei He;Yong Yuan;Xiawei Wei. Targeting inflammation as cancer therapy.. Journal of hematology & oncology(IF=40.4). 2024. PMID:38520006. DOI: 10.1186/s13045-024-01528-7.
  • [52] Amir R Afshari;Mehdi Sanati;Hamid Mollazadeh;Prashant Kesharwani;Thomas P Johnston;Amirhossein Sahebkar. Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways.. Seminars in cancer biology(IF=15.7). 2022. PMID:35115226. DOI: 10.1016/j.semcancer.2022.01.008.
  • [53] Kyohei Nakamura;Mark J Smyth. Targeting cancer-related inflammation in the era of immunotherapy.. Immunology and cell biology(IF=3.0). 2017. PMID:27999432. DOI: 10.1038/icb.2016.126.
  • [54] Shanthini M Crusz;Frances R Balkwill. Inflammation and cancer: advances and new agents.. Nature reviews. Clinical oncology(IF=82.2). 2015. PMID:26122183. DOI: 10.1038/nrclinonc.2015.105.
  • [55] Jun Zhang;Nirmal Veeramachaneni. Targeting interleukin-1β and inflammation in lung cancer.. Biomarker research(IF=11.5). 2022. PMID:35086565. DOI: 10.1186/s40364-021-00341-5.
  • [56] Yifei Xie;Fangfang Liu;Yunfei Wu;Yuer Zhu;Yanan Jiang;Qiong Wu;Zigang Dong;Kangdong Liu. Inflammation in cancer: therapeutic opportunities from new insights.. Molecular cancer(IF=33.9). 2025. PMID:39994787. DOI: 10.1186/s12943-025-02243-8.
  • [57] Eva Bagyinszky;Vo Van Giau;Kyuhwan Shim;Kyoungho Suk;Seong Soo A An;SangYun Kim. Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis.. Journal of the neurological sciences(IF=3.2). 2017. PMID:28431620. DOI: 10.1016/j.jns.2017.03.031.
  • [58] Zi-Zhen Si;Chen-Jun Zou;Xi Mei;Xiao-Fang Li;Hu Luo;Yao Shen;Jun Hu;Xing-Xing Li;Lun Wu;Yu Liu. Targeting neuroinflammation in Alzheimer's disease: from mechanisms to clinical applications.. Neural regeneration research(IF=6.7). 2023. PMID:36204826. DOI: 10.4103/1673-5374.353484.
  • [59] A Mancinella;M Mancinella;G Carpinteri;A Bellomo;C Fossati;V Gianturco;A Iori;E Ettorre;G Troisi;V Marigliano. Is there a relationship between high C-reactive protein (CRP) levels and dementia?. Archives of gerontology and geriatrics(IF=3.8). 2009. PMID:19836632. DOI: 10.1016/j.archger.2009.09.028.
  • [60] Keenan A Walker;Ron C Hoogeveen;Aaron R Folsom;Christie M Ballantyne;David S Knopman;B Gwen Windham;Clifford R Jack;Rebecca F Gottesman. Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study.. Neurology(IF=8.5). 2017. PMID:29093073. DOI: 10.1212/WNL.0000000000004688.
  • [61] C Holmes. Review: systemic inflammation and Alzheimer's disease.. Neuropathology and applied neurobiology(IF=3.4). 2013. PMID:23046210. DOI: 10.1111/j.1365-2990.2012.01307.x.
  • [62] Federico Licastro. Genomics of immune molecules: early detection of cognitive decline and new therapeutic interventions.. Expert review of neurotherapeutics(IF=3.4). 2002. PMID:19810979. DOI: 10.1586/14737175.2.5.639.
  • [63] Li Liu;Christina Chan. The role of inflammasome in Alzheimer's disease.. Ageing research reviews(IF=12.4). 2014. PMID:24561250. DOI: .
  • [64] Victoria Abbott;Benjamin E Housden;Annwyne Houldsworth. Could immunotherapy and regulatory T cells be used therapeutically to slow the progression of Alzheimer's disease?. Brain communications(IF=4.5). 2025. PMID:40078868. DOI: 10.1093/braincomms/fcaf092.
  • [65] Wei Li;Lin Sun;Ling Yue;Shifu Xiao. Alzheimer's disease and COVID-19: Interactions, intrinsic linkages, and the role of immunoinflammatory responses in this process.. Frontiers in immunology(IF=5.9). 2023. PMID:36845144. DOI: 10.3389/fimmu.2023.1120495.
  • [66] Philip B Gorelick. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials.. Annals of the New York Academy of Sciences(IF=4.8). 2010. PMID:20955439. DOI: 10.1111/j.1749-6632.2010.05726.x.
  • [67] Tanuja Chitnis;Howard L Weiner. CNS inflammation and neurodegeneration.. The Journal of clinical investigation(IF=13.6). 2017. PMID:28872464. DOI: .
  • [68] Alhamdu Adamu;Shuo Li;Fankai Gao;Guofang Xue. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets.. Frontiers in aging neuroscience(IF=4.5). 2024. PMID:38681666. DOI: 10.3389/fnagi.2024.1347987.
  • [69] Viviana Nociti;Marina Romozzi. The Role of BDNF in Multiple Sclerosis Neuroinflammation.. International journal of molecular sciences(IF=4.9). 2023. PMID:37176155. DOI: 10.3390/ijms24098447.
  • [70] Newshan Behrangi;Felix Fischbach;Markus Kipp. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action.. Cells(IF=5.2). 2019. PMID:30621015. DOI: 10.3390/cells8010024.
  • [71] Lorenza Tamberi;Alessia Belloni;Armanda Pugnaloni;Maria Rita Rippo;Fabiola Olivieri;Antonio Domenico Procopio;Giuseppe Bronte. The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases.. Cells(IF=5.2). 2024. PMID:38607083. DOI: 10.3390/cells13070643.
  • [72] Justyna Fołta;Zuzanna Rzepka;Dorota Wrześniok. The Role of Inflammation in Neurodegenerative Diseases: Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis.. International journal of molecular sciences(IF=4.9). 2025. PMID:40507988. DOI: 10.3390/ijms26115177.
  • [73] Yiping Su;Zhanguo Su. Effects of exercise on neuroinflammation in age-related neurodegenerative disorders.. European journal of medical research(IF=3.4). 2025. PMID:41024269. DOI: 10.1186/s40001-025-03165-3.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Inflammation · Chronic Diseases · Autoimmune Diseases · Cardiovascular Diseases · Cancer

© 2025 MaltSci